Company to Conduct Partnering Meetings Focused on Oncology, Liver Disease and Inflammatory Disease RAMAT GAN, Israel, June 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, today announced its participation in the BIO International Convention 2026, to be held June 22–25, 2026, in San Diego, California. BIO International Convention | June 22-25 | San Diego During the conference, Can-Fite will conduct partnering meetings with pharmaceutical companies, biotechnology firms, and potential strategic partners to discuss licensing and commercialization opportunities for its advanced clinical-stage pipeline. The Company's lead drug candidate, Namodenoson, is currently being evaluated in a pivotal Phase III study for advanced hepatocellular carcinoma (HCC), in pancreatic cancer following the successful completion of a Phase IIa study and conducting a Phase IIb study for MASH. Piclidenoson, Can-Fite's drug candidate for inflammatory diseases, is currently being evaluated in a pivotal Phase III study for psoriasis and is undertaking the preparatory work for a Phase II study in the rare genetic disease, Lowe Syndrome. Can-Fite's proprietary A3 adenosine receptor (A3AR) platform technology has demonstrated a favorable safety profile in more than 1,600 patients treated to date and serves as the foundation for the Company's pipeline of orally administered therapies targeting cancer, liver, and inflammatory diseases. The Company has established multiple regional licensing agreements for its drug candidates and continues to pursue strategic partnerships to maximize the global value of its pipeline. To date, these agreements have generated approximately $20 million in upfront and milestone payments, with the potential for additional milestone payments and royalties. "BIO International Convention is one of the most important partnering events in the biotechnology industry, bringing together companies seeking innovative therapeutic assets and strategic collaborations," said Dr. Sari Fishman, Vice President of Business Development at Can-Fite BioPharma. "With two pivotal Phase III programs, an ongoing Phase IIb study in MASH, and additional opportunities in oncology and rare diseases, we look forward to meeting with potential partners to discuss licensing, commercialization, and value-creating collaborations for our clinical-stage assets." Dr. Fishman will be available for partnering meetings throughout the conference. About Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company’s lead drug candidate, Piclidenoson recently reported topline results in a Phase 3 trial for psoriasis and commenced a pivotal Phase 3 trial. Can-Fite’s liver drug, Namodenoson, is being evaluated in a Phase III trial for hepatocellular carcinoma (HCC), a Phase 2b trial for the treatment of MASH, and in a Phase 2a study in pancreatic cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,600 patients in clinical studies to date. For more information please visit: www.canfite.com . Forward-Looking Statements This press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts. All statements in this communication, other than those relating to historical facts, are “forward looking statements”. Forward-looking statements can be identified by the use of forward-looking words such as “believe,” “expect,” “intend,” “plan,” “may,” “should” or “anticipate” or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. For example, the Company is using forward-looking statements when it discusses the completion of the offerings, the satisfaction of customary closing conditions related to the offerings and the intended use of proceeds therefrom. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainti